View Valuationevertex fabrinology 将来の成長Future 基準チェック /06現在、 evertex fabrinologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Luxury 収益成長13.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 17First quarter 2026 earnings released: EPS: NT$0.31 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.31 (up from NT$0.23 in 1Q 2025). Revenue: NT$191.3m (down 11% from 1Q 2025). Net income: NT$26.7m (up 36% from 1Q 2025). Profit margin: 14% (up from 9.2% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$0.78 (vs NT$1.14 in FY 2024)Full year 2025 results: EPS: NT$0.78 (down from NT$1.14 in FY 2024). Revenue: NT$803.7m (up 2.0% from FY 2024). Net income: NT$67.3m (down 31% from FY 2024). Profit margin: 8.4% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 10evertex fabrinology limited, Annual General Meeting, Jun 23, 2026evertex fabrinology limited, Annual General Meeting, Jun 23, 2026. Location: no,9, jung an rd., nei ts`uo li, lujhu district, taoyuan city TaiwanReported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$0.25 (vs NT$0.13 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.25 (up from NT$0.13 in 3Q 2024). Revenue: NT$179.8m (down 8.5% from 3Q 2024). Net income: NT$21.5m (up 90% from 3Q 2024). Profit margin: 12% (up from 5.8% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.New Risk • Aug 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.9% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 178% Cash payout ratio: 215% Minor Risks Profit margins are more than 30% lower than last year (5.9% net profit margin). Market cap is less than US$100m (NT$1.71b market cap, or US$56.8m).Reported Earnings • Aug 19Second quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.27 profit in 2Q 2024)Second quarter 2025 results: NT$0.16 loss per share (down from NT$0.27 profit in 2Q 2024). Revenue: NT$198.7m (up 6.4% from 2Q 2024). Net loss: NT$13.6m (down 158% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jul 08Upcoming dividend of NT$1.01 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.6%. Lower than top quartile of Taiwanese dividend payers (5.3%). In line with average of industry peers (4.5%).Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$21.75, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 17x in the Luxury industry in Taiwan. Negligible returns to shareholders over past three years.Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.36 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (down from NT$0.36 in 1Q 2024). Revenue: NT$213.9m (up 13% from 1Q 2024). Net income: NT$19.7m (down 37% from 1Q 2024). Profit margin: 9.2% (down from 16% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Declared Dividend • May 12Dividend increased to NT$1.01Dividend of NT$1.01 is 74% higher than last year. Ex-date: 15th July 2025 Payment date: 15th August 2025 Dividend yield will be 3.8%, which is lower than the industry average of 4.3%. Sustainability & Growth Dividend is covered by earnings (89% earnings payout ratio) but not covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 5.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • May 01evertex fabrinology limited to Report Q1, 2025 Results on May 09, 2025evertex fabrinology limited announced that they will report Q1, 2025 results on May 09, 2025Reported Earnings • Mar 19Full year 2024 earnings released: EPS: NT$1.13 (vs NT$0.57 in FY 2023)Full year 2024 results: EPS: NT$1.13 (up from NT$0.57 in FY 2023). Revenue: NT$788.0m (up 20% from FY 2023). Net income: NT$97.3m (up 97% from FY 2023). Profit margin: 12% (up from 7.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 13evertex fabrinology limited, Annual General Meeting, Jun 26, 2025evertex fabrinology limited, Annual General Meeting, Jun 26, 2025. Location: no,9, jung an rd., nei ts`uo li, lujhu district, taoyuan city Taiwanお知らせ • Mar 04evertex fabrinology limited to Report Q4, 2024 Results on Mar 12, 2025evertex fabrinology limited announced that they will report Q4, 2024 results on Mar 12, 2025分析記事 • Nov 19Investors Shouldn't Be Too Comfortable With evertex fabrinology's (TWSE:1470) EarningsDespite posting some strong earnings, the market for evertex fabrinology limited's ( TWSE:1470 ) stock hasn't moved...Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.064 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.064 in 3Q 2023). Revenue: NT$196.6m (up 35% from 3Q 2023). Net income: NT$11.3m (up 106% from 3Q 2023). Profit margin: 5.8% (up from 3.8% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.分析記事 • Sep 16evertex fabrinology limited's (TWSE:1470) Business Is Yet to Catch Up With Its Share Priceevertex fabrinology limited's ( TWSE:1470 ) price-to-earnings (or "P/E") ratio of 32.9x might make it look like a...Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$24.60, the stock trades at a trailing P/E ratio of 35.1x. Average trailing P/E is 20x in the Luxury industry in Taiwan. Total returns to shareholders of 64% over the past three years.Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.10 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.10 in 2Q 2023). Revenue: NT$186.7m (up 25% from 2Q 2023). Net income: NT$23.4m (up 174% from 2Q 2023). Profit margin: 13% (up from 5.7% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • Aug 02evertex fabrinology limited to Report Q2, 2024 Results on Aug 09, 2024evertex fabrinology limited announced that they will report Q2, 2024 results on Aug 09, 2024Upcoming Dividend • Jul 08Upcoming dividend of NT$0.58 per shareEligible shareholders must have bought the stock before 15 July 2024. Payment date: 16 August 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (3.1%).Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.41 in 1Q 2023)First quarter 2024 results: EPS: NT$0.36 (down from NT$0.41 in 1Q 2023). Revenue: NT$190.3m (down 18% from 1Q 2023). Net income: NT$31.1m (down 12% from 1Q 2023). Profit margin: 16% (up from 15% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Declared Dividend • May 12Dividend increased to NT$0.58Dividend of NT$0.58 is 29% higher than last year. Ex-date: 15th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.0%, which is lower than the industry average of 4.3%. Sustainability & Growth Dividend is not covered by earnings (101% earnings payout ratio). However, it is well covered by cash flows (45% cash payout ratio). The dividend has increased by an average of 6.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 12% to bring the payout ratio under control. However, EPS has remained steady over the last 5 years so the company would need to improve on their historical growth rates.お知らせ • May 11Evertex Fabrinology Ltd. Announces Cash Dividend, Payable on August 16, 2024Evertex Fabrinology Ltd. announced cash dividend to common share holders of TWD 49,744,860 (TWD 0.58 per share). Ex-rights (ex-dividend) trading date is July 15, 2024. Last date before book closure is July 16, 2024. Book closure starting date is July 17, 2024. Book closure ending date is July 21, 2024. Ex-rights (ex-dividend) record date is July 21, 2024. Payment date of common stock cash dividend distribution is August 16, 2024.お知らせ • May 03evertex fabrinology limited to Report Q1, 2024 Results on May 10, 2024evertex fabrinology limited announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 10, 2024分析記事 • Mar 20evertex fabrinology's (TWSE:1470) Profits May Not Reveal Underlying Issuesevertex fabrinology limited's ( TWSE:1470 ) stock didn't jump after it announced some healthy earnings. We think that...Reported Earnings • Mar 15Full year 2023 earnings released: EPS: NT$0.58 (vs NT$0.38 in FY 2022)Full year 2023 results: EPS: NT$0.58 (up from NT$0.38 in FY 2022). Revenue: NT$655.2m (down 23% from FY 2022). Net income: NT$49.3m (up 50% from FY 2022). Profit margin: 7.5% (up from 3.9% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 4% per year.お知らせ • Mar 09evertex fabrinology limited, Annual General Meeting, Jun 25, 2024evertex fabrinology limited, Annual General Meeting, Jun 25, 2024. Location: No.9 Rong’an Rd., Luzhu Dist., Taoyuan City 338028, Taiwan Taoyuan City Taiwan Agenda: To consider Report on 2023 Business Report; to Report on 2023 Audit Committee's Review Report; to Report on 2023 ”Procedures for Loaning Funds to Others”and ”Procedures for Endorsements and Guarantees”; to Report on 2023 Distribution of Remunerations to Employees & Directors; to Report on the second half of 2023 Earnings of cash dividend distribution; to Report on amendments to the Internal Regulations; to Ratification of the 2023 Business Report and Financial Statements; and to consider other matters if any.Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.06 (vs NT$0.15 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.06 (down from NT$0.15 in 3Q 2022). Revenue: NT$145.6m (down 36% from 3Q 2022). Net income: NT$5.49m (down 56% from 3Q 2022). Profit margin: 3.8% (down from 5.6% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$0.10 (vs NT$0.071 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.10 (up from NT$0.071 loss in 2Q 2022). Revenue: NT$149.5m (down 29% from 2Q 2022). Net income: NT$8.54m (up NT$14.6m from 2Q 2022). Profit margin: 5.7% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jul 20Upcoming dividend of NT$0.45 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 July 2023. Payment date: 18 August 2023. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (4.4%).Reported Earnings • Mar 30Full year 2022 earnings released: EPS: NT$0.38 (vs NT$0.76 in FY 2021)Full year 2022 results: EPS: NT$0.38 (down from NT$0.76 in FY 2021). Revenue: NT$845.2m (down 5.5% from FY 2021). Net income: NT$32.8m (down 50% from FY 2021). Profit margin: 3.9% (down from 7.3% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Wu Zhong Liao was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.07 loss per share (vs NT$0.34 profit in 2Q 2021)Second quarter 2022 results: NT$0.07 loss per share (down from NT$0.34 profit in 2Q 2021). Revenue: NT$209.3m (down 11% from 2Q 2021). Net loss: NT$6.06m (down 121% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 4% per year.Upcoming Dividend • Jul 21Upcoming dividend of NT$0.80 per shareEligible shareholders must have bought the stock before 28 July 2022. Payment date: 19 August 2022. Payout ratio and cash payout ratio are on the higher end at 80% and 77% respectively. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (6.7%). In line with average of industry peers (4.0%).Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$23.65, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 14x in the Luxury industry in Taiwan. Total returns to shareholders of 15% over the past three years.Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.31 (vs NT$0.076 in 1Q 2021)First quarter 2022 results: EPS: NT$0.31 (up from NT$0.076 in 1Q 2021). Revenue: NT$299.9m (up 49% from 1Q 2021). Net income: NT$26.9m (up 315% from 1Q 2021). Profit margin: 9.0% (up from 3.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Wu Zhong Liao was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$25.05, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Luxury industry in Taiwan. Total returns to shareholders of 24% over the past three years.Reported Earnings • Apr 02Full year 2021 earnings released: EPS: NT$0.76 (vs NT$0.41 in FY 2020)Full year 2021 results: EPS: NT$0.76 (up from NT$0.41 in FY 2020). Revenue: NT$894.8m (up 42% from FY 2020). Net income: NT$65.2m (up 84% from FY 2020). Profit margin: 7.3% (up from 5.6% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.15 (vs NT$0.11 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: NT$243.5m (up 54% from 3Q 2020). Net income: NT$12.7m (up 34% from 3Q 2020). Profit margin: 5.2% (down from 6.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.11 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$234.5m (up 168% from 2Q 2020). Net income: NT$29.4m (up NT$38.7m from 2Q 2020). Profit margin: 13% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 4% per year.Upcoming Dividend • Jul 22Upcoming dividend of NT$0.42 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 20 August 2021. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). In line with average of industry peers (2.5%).分析記事 • Apr 25Does evertex fabrinology limited (TPE:1470) Have A Place In Your Dividend Stock Portfolio?Is evertex fabrinology limited ( TPE:1470 ) a good dividend stock? How can we tell? Dividend paying companies with...Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$0.41 (vs NT$0.89 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$630.8m (down 23% from FY 2019). Net income: NT$35.4m (down 53% from FY 2019). Profit margin: 5.6% (down from 9.3% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.分析記事 • Mar 26Be Wary Of evertex fabrinology (TPE:1470) And Its Returns On CapitalWhen we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...分析記事 • Mar 05evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?evertex fabrinology's (TPE:1470) stock is up by 3.1% over the past month. However, its weak financial performance...分析記事 • Feb 12Does evertex fabrinology's (TPE:1470) Statutory Profit Adequately Reflect Its Underlying Profit?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...分析記事 • Jan 25Tread With Caution Around evertex fabrinology limited's (TPE:1470) 4.6% Dividend YieldDividend paying stocks like evertex fabrinology limited ( TPE:1470 ) tend to be popular with investors, and for good...Is New 90 Day High Low • Jan 20New 90-day low: NT$17.55The company is down 5.0% from its price of NT$18.40 on 22 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 1.0% over the same period.分析記事 • Jan 07Would Shareholders Who Purchased evertex fabrinology's (TPE:1470) Stock Year Be Happy With The Share price Today?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...分析記事 • Dec 20Is evertex fabrinology (TPE:1470) Headed For Trouble?If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...分析記事 • Dec 02evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?evertex fabrinology's (TPE:1470) stock is up by 2.0% over the past week. However, its weak financial performance...Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.11The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$158.5m (down 23% from 3Q 2019). Net income: NT$9.49m (down 47% from 3Q 2019). Profit margin: 6.0% (down from 8.6% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Sep 24New 90-day low: NT$17.50The company is down 8.0% from its price of NT$19.00 on 23 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 1.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、evertex fabrinology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:1470 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20267817463103N/A12/31/20258046762101N/A9/30/2025807596595N/A6/30/2025824494071N/A3/31/2025812867599N/A12/31/20247889785111N/A9/30/2024702664971N/A6/30/2024651607497N/A3/31/202461345110145N/A12/31/202365549111145N/A9/30/202363749110141N/A6/30/202371756183206N/A3/31/202377741182211N/A12/31/202284533162189N/A9/30/202295150201237N/A6/30/20229685088128N/A3/31/2022993864780N/A12/31/202189565-144N/A9/30/202185867-306N/A6/30/202177363-3318N/A3/31/202162625-2436N/A12/31/2020631351776N/A9/30/2020647322794N/A6/30/20206954073132N/A3/31/20208157271119N/A12/31/201981876N/A94N/A9/30/201981479N/A93N/A6/30/201980277N/A76N/A3/31/201979262N/A98N/A12/31/201875449N/A106N/A9/30/201873547N/A99N/A6/30/201870436N/A91N/A3/31/201869340N/A89N/A12/31/201770142N/A99N/A9/30/201771142N/A107N/A6/30/201770339N/A104N/A3/31/201768240N/A113N/A12/31/201668647N/A122N/A9/30/201668750N/A127N/A6/30/201671364N/A136N/A3/31/201674562N/A99N/A12/31/201576261N/A87N/A9/30/201577063N/A77N/A6/30/201574754N/A70N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1470の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1470の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1470の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1470の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1470の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1470の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-durables 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/19 16:49終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋evertex fabrinology limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 17First quarter 2026 earnings released: EPS: NT$0.31 (vs NT$0.23 in 1Q 2025)First quarter 2026 results: EPS: NT$0.31 (up from NT$0.23 in 1Q 2025). Revenue: NT$191.3m (down 11% from 1Q 2025). Net income: NT$26.7m (up 36% from 1Q 2025). Profit margin: 14% (up from 9.2% in 1Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: NT$0.78 (vs NT$1.14 in FY 2024)Full year 2025 results: EPS: NT$0.78 (down from NT$1.14 in FY 2024). Revenue: NT$803.7m (up 2.0% from FY 2024). Net income: NT$67.3m (down 31% from FY 2024). Profit margin: 8.4% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 10evertex fabrinology limited, Annual General Meeting, Jun 23, 2026evertex fabrinology limited, Annual General Meeting, Jun 23, 2026. Location: no,9, jung an rd., nei ts`uo li, lujhu district, taoyuan city Taiwan
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$0.25 (vs NT$0.13 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.25 (up from NT$0.13 in 3Q 2024). Revenue: NT$179.8m (down 8.5% from 3Q 2024). Net income: NT$21.5m (up 90% from 3Q 2024). Profit margin: 12% (up from 5.8% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 19New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.9% Last year net profit margin: 9.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 178% Cash payout ratio: 215% Minor Risks Profit margins are more than 30% lower than last year (5.9% net profit margin). Market cap is less than US$100m (NT$1.71b market cap, or US$56.8m).
Reported Earnings • Aug 19Second quarter 2025 earnings released: NT$0.16 loss per share (vs NT$0.27 profit in 2Q 2024)Second quarter 2025 results: NT$0.16 loss per share (down from NT$0.27 profit in 2Q 2024). Revenue: NT$198.7m (up 6.4% from 2Q 2024). Net loss: NT$13.6m (down 158% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jul 08Upcoming dividend of NT$1.01 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 15 August 2025. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.6%. Lower than top quartile of Taiwanese dividend payers (5.3%). In line with average of industry peers (4.5%).
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$21.75, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 17x in the Luxury industry in Taiwan. Negligible returns to shareholders over past three years.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.36 in 1Q 2024)First quarter 2025 results: EPS: NT$0.23 (down from NT$0.36 in 1Q 2024). Revenue: NT$213.9m (up 13% from 1Q 2024). Net income: NT$19.7m (down 37% from 1Q 2024). Profit margin: 9.2% (down from 16% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Declared Dividend • May 12Dividend increased to NT$1.01Dividend of NT$1.01 is 74% higher than last year. Ex-date: 15th July 2025 Payment date: 15th August 2025 Dividend yield will be 3.8%, which is lower than the industry average of 4.3%. Sustainability & Growth Dividend is covered by earnings (89% earnings payout ratio) but not covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 5.3% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 5.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • May 01evertex fabrinology limited to Report Q1, 2025 Results on May 09, 2025evertex fabrinology limited announced that they will report Q1, 2025 results on May 09, 2025
Reported Earnings • Mar 19Full year 2024 earnings released: EPS: NT$1.13 (vs NT$0.57 in FY 2023)Full year 2024 results: EPS: NT$1.13 (up from NT$0.57 in FY 2023). Revenue: NT$788.0m (up 20% from FY 2023). Net income: NT$97.3m (up 97% from FY 2023). Profit margin: 12% (up from 7.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 13evertex fabrinology limited, Annual General Meeting, Jun 26, 2025evertex fabrinology limited, Annual General Meeting, Jun 26, 2025. Location: no,9, jung an rd., nei ts`uo li, lujhu district, taoyuan city Taiwan
お知らせ • Mar 04evertex fabrinology limited to Report Q4, 2024 Results on Mar 12, 2025evertex fabrinology limited announced that they will report Q4, 2024 results on Mar 12, 2025
分析記事 • Nov 19Investors Shouldn't Be Too Comfortable With evertex fabrinology's (TWSE:1470) EarningsDespite posting some strong earnings, the market for evertex fabrinology limited's ( TWSE:1470 ) stock hasn't moved...
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.13 (vs NT$0.064 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.13 (up from NT$0.064 in 3Q 2023). Revenue: NT$196.6m (up 35% from 3Q 2023). Net income: NT$11.3m (up 106% from 3Q 2023). Profit margin: 5.8% (up from 3.8% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
分析記事 • Sep 16evertex fabrinology limited's (TWSE:1470) Business Is Yet to Catch Up With Its Share Priceevertex fabrinology limited's ( TWSE:1470 ) price-to-earnings (or "P/E") ratio of 32.9x might make it look like a...
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$24.60, the stock trades at a trailing P/E ratio of 35.1x. Average trailing P/E is 20x in the Luxury industry in Taiwan. Total returns to shareholders of 64% over the past three years.
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.10 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.10 in 2Q 2023). Revenue: NT$186.7m (up 25% from 2Q 2023). Net income: NT$23.4m (up 174% from 2Q 2023). Profit margin: 13% (up from 5.7% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • Aug 02evertex fabrinology limited to Report Q2, 2024 Results on Aug 09, 2024evertex fabrinology limited announced that they will report Q2, 2024 results on Aug 09, 2024
Upcoming Dividend • Jul 08Upcoming dividend of NT$0.58 per shareEligible shareholders must have bought the stock before 15 July 2024. Payment date: 16 August 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (3.1%).
Reported Earnings • May 19First quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.41 in 1Q 2023)First quarter 2024 results: EPS: NT$0.36 (down from NT$0.41 in 1Q 2023). Revenue: NT$190.3m (down 18% from 1Q 2023). Net income: NT$31.1m (down 12% from 1Q 2023). Profit margin: 16% (up from 15% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Declared Dividend • May 12Dividend increased to NT$0.58Dividend of NT$0.58 is 29% higher than last year. Ex-date: 15th July 2024 Payment date: 16th August 2024 Dividend yield will be 3.0%, which is lower than the industry average of 4.3%. Sustainability & Growth Dividend is not covered by earnings (101% earnings payout ratio). However, it is well covered by cash flows (45% cash payout ratio). The dividend has increased by an average of 6.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 12% to bring the payout ratio under control. However, EPS has remained steady over the last 5 years so the company would need to improve on their historical growth rates.
お知らせ • May 11Evertex Fabrinology Ltd. Announces Cash Dividend, Payable on August 16, 2024Evertex Fabrinology Ltd. announced cash dividend to common share holders of TWD 49,744,860 (TWD 0.58 per share). Ex-rights (ex-dividend) trading date is July 15, 2024. Last date before book closure is July 16, 2024. Book closure starting date is July 17, 2024. Book closure ending date is July 21, 2024. Ex-rights (ex-dividend) record date is July 21, 2024. Payment date of common stock cash dividend distribution is August 16, 2024.
お知らせ • May 03evertex fabrinology limited to Report Q1, 2024 Results on May 10, 2024evertex fabrinology limited announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 10, 2024
分析記事 • Mar 20evertex fabrinology's (TWSE:1470) Profits May Not Reveal Underlying Issuesevertex fabrinology limited's ( TWSE:1470 ) stock didn't jump after it announced some healthy earnings. We think that...
Reported Earnings • Mar 15Full year 2023 earnings released: EPS: NT$0.58 (vs NT$0.38 in FY 2022)Full year 2023 results: EPS: NT$0.58 (up from NT$0.38 in FY 2022). Revenue: NT$655.2m (down 23% from FY 2022). Net income: NT$49.3m (up 50% from FY 2022). Profit margin: 7.5% (up from 3.9% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 4% per year.
お知らせ • Mar 09evertex fabrinology limited, Annual General Meeting, Jun 25, 2024evertex fabrinology limited, Annual General Meeting, Jun 25, 2024. Location: No.9 Rong’an Rd., Luzhu Dist., Taoyuan City 338028, Taiwan Taoyuan City Taiwan Agenda: To consider Report on 2023 Business Report; to Report on 2023 Audit Committee's Review Report; to Report on 2023 ”Procedures for Loaning Funds to Others”and ”Procedures for Endorsements and Guarantees”; to Report on 2023 Distribution of Remunerations to Employees & Directors; to Report on the second half of 2023 Earnings of cash dividend distribution; to Report on amendments to the Internal Regulations; to Ratification of the 2023 Business Report and Financial Statements; and to consider other matters if any.
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: NT$0.06 (vs NT$0.15 in 3Q 2022)Third quarter 2023 results: EPS: NT$0.06 (down from NT$0.15 in 3Q 2022). Revenue: NT$145.6m (down 36% from 3Q 2022). Net income: NT$5.49m (down 56% from 3Q 2022). Profit margin: 3.8% (down from 5.6% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$0.10 (vs NT$0.071 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.10 (up from NT$0.071 loss in 2Q 2022). Revenue: NT$149.5m (down 29% from 2Q 2022). Net income: NT$8.54m (up NT$14.6m from 2Q 2022). Profit margin: 5.7% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jul 20Upcoming dividend of NT$0.45 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 July 2023. Payment date: 18 August 2023. Payout ratio is on the higher end at 94%, however this is supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (4.4%).
Reported Earnings • Mar 30Full year 2022 earnings released: EPS: NT$0.38 (vs NT$0.76 in FY 2021)Full year 2022 results: EPS: NT$0.38 (down from NT$0.76 in FY 2021). Revenue: NT$845.2m (down 5.5% from FY 2021). Net income: NT$32.8m (down 50% from FY 2021). Profit margin: 3.9% (down from 7.3% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Wu Zhong Liao was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.07 loss per share (vs NT$0.34 profit in 2Q 2021)Second quarter 2022 results: NT$0.07 loss per share (down from NT$0.34 profit in 2Q 2021). Revenue: NT$209.3m (down 11% from 2Q 2021). Net loss: NT$6.06m (down 121% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 4% per year.
Upcoming Dividend • Jul 21Upcoming dividend of NT$0.80 per shareEligible shareholders must have bought the stock before 28 July 2022. Payment date: 19 August 2022. Payout ratio and cash payout ratio are on the higher end at 80% and 77% respectively. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (6.7%). In line with average of industry peers (4.0%).
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$23.65, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 14x in the Luxury industry in Taiwan. Total returns to shareholders of 15% over the past three years.
Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.31 (vs NT$0.076 in 1Q 2021)First quarter 2022 results: EPS: NT$0.31 (up from NT$0.076 in 1Q 2021). Revenue: NT$299.9m (up 49% from 1Q 2021). Net income: NT$26.9m (up 315% from 1Q 2021). Profit margin: 9.0% (up from 3.2% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Wu Zhong Liao was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$25.05, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 18x in the Luxury industry in Taiwan. Total returns to shareholders of 24% over the past three years.
Reported Earnings • Apr 02Full year 2021 earnings released: EPS: NT$0.76 (vs NT$0.41 in FY 2020)Full year 2021 results: EPS: NT$0.76 (up from NT$0.41 in FY 2020). Revenue: NT$894.8m (up 42% from FY 2020). Net income: NT$65.2m (up 84% from FY 2020). Profit margin: 7.3% (up from 5.6% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS NT$0.15 (vs NT$0.11 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: NT$243.5m (up 54% from 3Q 2020). Net income: NT$12.7m (up 34% from 3Q 2020). Profit margin: 5.2% (down from 6.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.11 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$234.5m (up 168% from 2Q 2020). Net income: NT$29.4m (up NT$38.7m from 2Q 2020). Profit margin: 13% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 4% per year.
Upcoming Dividend • Jul 22Upcoming dividend of NT$0.42 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 20 August 2021. Trailing yield: 2.6%. Lower than top quartile of Taiwanese dividend payers (4.9%). In line with average of industry peers (2.5%).
分析記事 • Apr 25Does evertex fabrinology limited (TPE:1470) Have A Place In Your Dividend Stock Portfolio?Is evertex fabrinology limited ( TPE:1470 ) a good dividend stock? How can we tell? Dividend paying companies with...
Reported Earnings • Mar 30Full year 2020 earnings released: EPS NT$0.41 (vs NT$0.89 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$630.8m (down 23% from FY 2019). Net income: NT$35.4m (down 53% from FY 2019). Profit margin: 5.6% (down from 9.3% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
分析記事 • Mar 26Be Wary Of evertex fabrinology (TPE:1470) And Its Returns On CapitalWhen we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
分析記事 • Mar 05evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?evertex fabrinology's (TPE:1470) stock is up by 3.1% over the past month. However, its weak financial performance...
分析記事 • Feb 12Does evertex fabrinology's (TPE:1470) Statutory Profit Adequately Reflect Its Underlying Profit?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
分析記事 • Jan 25Tread With Caution Around evertex fabrinology limited's (TPE:1470) 4.6% Dividend YieldDividend paying stocks like evertex fabrinology limited ( TPE:1470 ) tend to be popular with investors, and for good...
Is New 90 Day High Low • Jan 20New 90-day low: NT$17.55The company is down 5.0% from its price of NT$18.40 on 22 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 1.0% over the same period.
分析記事 • Jan 07Would Shareholders Who Purchased evertex fabrinology's (TPE:1470) Stock Year Be Happy With The Share price Today?Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...
分析記事 • Dec 20Is evertex fabrinology (TPE:1470) Headed For Trouble?If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...
分析記事 • Dec 02evertex fabrinology limited's (TPE:1470) Financial Prospects Don't Look Very Positive: Could It Mean A Stock Price Drop In The Future?evertex fabrinology's (TPE:1470) stock is up by 2.0% over the past week. However, its weak financial performance...
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.11The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$158.5m (down 23% from 3Q 2019). Net income: NT$9.49m (down 47% from 3Q 2019). Profit margin: 6.0% (down from 8.6% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Sep 24New 90-day low: NT$17.50The company is down 8.0% from its price of NT$19.00 on 23 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 1.0% over the same period.